Comparison Study of the Effect of Aliskiren Versus Negative Controls on

Status Completed

Clinical Trial Summary

Marfan syndrome (MFS) is an inherited disorder of connective tissue with morbidity and mortality from aortic dilatation and dissection. The current standard of care is beta-blocker (BB) treatment and therapeutic target is heart rate. The degree of aortic dilatation and response to BB vary in adults with MFS. However, aortic stiffness is often present, and can be a predictor of aortic dilatation and cardiovascular complications. Aortic stiffness is a logical therapeutic target in adults with MFS.

Transforming growth factor beta(TGF-beta) mediates disease pathogenesis in MFS and contributes to aortic stiffness. Cross-talk between TGF-beta system and renin-angiotensin system (RAS) has been demonstrated. The angiotensin receptor blocker (ARB), losartan, inhibits TGF-beta activity and reverses aortic wall pathology in a Marfan mouse model. In a small cohort study, the use of ARB therapy (losartan or irbesartan) significantly slowed the rate of progressive aortic dilatation in patients with MFS, after BB therapy had failed to prevent aortic root dilatation. In another study, angiotensin converting enzyme inhibitor, perindopril, reduced both aortic stiffness and aortic root diameter in patients with MFS taking standard BB therapy. Renin inhibitor, aliskiren, has not been studied to reduce aortic stiffness and attenuate aortic dilatation in patients with MFS.

This trial is a randomized, open-label trial of 32 patients with Marfan syndrome, treated with 6 months of aliskiren vs. negative controls in patients with MFS under atenolol treatment. MRI for aortic pulsed wave velocity (PWV) and distensibility, measurements of central BP (CBP) and augmentation index (AIx) will be performed at the beginning and end of treatment. A blood drawn for serum markers of TGF-beta, extracellular matrix turnover and inflammation will also be performed at 0 and 6 months. We plan to determine whether aliskiren decreases aortic stiffness significantly more than negative controls in patients with MFS under atenolol treatment.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01715207
Study type	Interventional
Source	Samsung Medical Center
Contact
Status	Completed
Phase	Phase 3
Start date	June 2010
Completion date	December 2014

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT00763893` - Study of the Efficacy of Losartan on Aortic Dilatation in Patients With Marfan Syndrome	Phase 3
Recruiting	`NCT05809323` - Marfan Syndrome Moderate Exercise Trial II	N/A
Completed	`NCT04776668` - Living With Marfan Syndrome and Your Aorta
Recruiting	`NCT01949233` - The Oxford Marfan Trial	Phase 2
Active, not recruiting	`NCT01145612` - Atenolol Versus Losartan in the Prevention of Progressive Dilation of the Aorta in Marfan Syndrome	Phase 3
Completed	`NCT00723801` - Effects of Losartan Versus Atenolol on Aortic and Cardiac Muscle Stiffness in Adults With Marfan Syndrome	Phase 3
Completed	`NCT04641325` - Marfan Syndrome Moderate Exercise Pilot	N/A
Recruiting	`NCT06257004` - Genome-wide Epistasis for Cardiovascular Severity in Marfan Study
Completed	`NCT01322165` - National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions	N/A
Recruiting	`NCT05700175` - Transcriptomic Study of Adult Population With Marfan Syndrome
Completed	`NCT00782327` - Randomized, Double-blind Study for the Evaluation of the Effect of Losartan Versus Placebo on Aortic Root Dilatation in Patients With Marfan Syndrome Under Treatment With Beta-blockers	Phase 3
Not yet recruiting	`NCT05838235` - Adapted Physical Activity Program (APA) for Effort Rehabilitation of Children and Teenagers With Marfan Syndrome	N/A
Recruiting	`NCT02148900` - Development of a Blood Test for Marfan Syndrome	N/A
Active, not recruiting	`NCT05980104` - Single-Session "Empowered Relief" Class for Marfan Syndrome and Related Conditions	N/A
Recruiting	`NCT02050113` - Complex Aortic Aneurysm Repair Using Physician Modified Endografts and Custom Made Devices	N/A
Completed	`NCT00001641` - Study of Heritable Connective Tissue Disorders	N/A
Completed	`NCT05516043` - Safety and Performance of POLYTHESE® Vascular Prosthesis
Recruiting	`NCT04776681` - Living With Marfans and Your Aorta: Surgical Outcomes Study
Completed	`NCT03236571` - Cardiorespiratory and Muscular Rehabilitation of Children and Young Adults With Marfan Syndrome.	N/A
Recruiting	`NCT00683124` - Nebivolol Versus Losartan Versus Nebivolol+Losartan Against Aortic Root Dilation in Genotyped Marfan Patients	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Comparison Study of the Effect of Aliskiren Versus Negative Controls on Aortic Stiffness in Patients With Marfan Syndrome Under Treatment With Atenolol

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms